神経治療学
Online ISSN : 2189-7824
Print ISSN : 0916-8443
ISSN-L : 2189-7824
シンポジウム8:チャレンジ! 遺伝性末梢神経疾患治療
副腎白質ジストロフィーに対する造血幹細胞移植の適応と有効性
松川 敬志
著者情報
ジャーナル フリー

2021 年 38 巻 3 号 p. 384-387

詳細
抄録

Adrenoleukodystrophy (ALD) is an X–linked neurodegenerative disorder sometimes accompanied with adrenal insufficiency. The causative gene is ABCD1. Wide variety of phenotypes is the characteristic of ALD even in the same family. For childhood–onset cerebral ALD (CCALD) at early stages, hematopoietic stem cell transplantation (HSCT) is effective to stop the progression of inflammatory demyelination of the cerebral white matter. For adult–onset cerebral ALD (ACALD), there were little experience of HSCT. We performed HSCT for adult–onset cerebral/cerebellobrainstem form ALD patients at early stages (8 ACALD patients and 4 cerebellobrainstem form patients). The survival probability was significantly better in patients who underwent HSCT compared with patients who did not undergo HSCT (P=0.0089). For all the patients who underwent HSCT, symptoms caused by cerebral/cerebellobrainstem white matter lesions became stable or partially improved after HSCT. Gadolinium–enhancement on brain MRI was disappeared/obscured in all the patients after HSCT. Enlarging white matter lesions became stable within one year after HSCT in all the patients. In 7 patients, white matter lesions reduced in size after HSCT. For ACALD and cerebellobrainstem form ALD patients at early stages, HSCT is effective to stop the progression of inflammatory demyelination of white matter lesions.

著者関連情報
© 2021 日本神経治療学会
前の記事 次の記事
feedback
Top